767 related articles for article (PubMed ID: 27760321)
21. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.
Wang T; Pine AR; Kotini AG; Yuan H; Zamparo L; Starczynowski DT; Leslie C; Papapetrou EP
Cell Stem Cell; 2021 Jun; 28(6):1074-1089.e7. PubMed ID: 33571445
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
[TBL] [Abstract][Full Text] [Related]
23. The N
Vu LP; Pickering BF; Cheng Y; Zaccara S; Nguyen D; Minuesa G; Chou T; Chow A; Saletore Y; MacKay M; Schulman J; Famulare C; Patel M; Klimek VM; Garrett-Bakelman FE; Melnick A; Carroll M; Mason CE; Jaffrey SR; Kharas MG
Nat Med; 2017 Nov; 23(11):1369-1376. PubMed ID: 28920958
[TBL] [Abstract][Full Text] [Related]
24. An
Lin S; Larrue C; Scheidegger NK; Seong BKA; Dharia NV; Kuljanin M; Wechsler CS; Kugener G; Robichaud AL; Conway AS; Mashaka T; Mouche S; Adane B; Ryan JA; Mancias JD; Younger ST; Piccioni F; Lee LH; Wunderlich M; Letai A; Tamburini J; Stegmaier K
Cancer Discov; 2022 Feb; 12(2):432-449. PubMed ID: 34531254
[TBL] [Abstract][Full Text] [Related]
25. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.
Rathe SK; Moriarity BS; Stoltenberg CB; Kurata M; Aumann NK; Rahrmann EP; Bailey NJ; Melrose EG; Beckmann DA; Liska CR; Largaespada DA
Sci Rep; 2014 Aug; 4():6048. PubMed ID: 25116387
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
27. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.
Liu L; Zhang J; Zhang X; Cheng P; Liu L; Huang Q; Liu H; Ren S; Wei P; Wang C; Dou C; Chen L; Liu X; Zhang H; Chen M
J Mol Med (Berl); 2021 Jan; 99(1):107-118. PubMed ID: 33128580
[TBL] [Abstract][Full Text] [Related]
28. Apicidin confers promising therapeutic effect on acute myeloid leukemia cells via increasing QPCT expression.
Liu L; Liu H; Liu L; Huang Q; Yang C; Cheng P; Ren S; Zhang J; Yu M; Ma X; Song W; Chen L; Zhang H; Chen M; Zhang X
Cancer Biol Ther; 2023 Dec; 24(1):2228497. PubMed ID: 37381175
[TBL] [Abstract][Full Text] [Related]
29. Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.
Irandoust M; Alvarez Zarate J; Hubeek I; van Beek EM; Schornagel K; Broekhuizen AJ; Akyuz M; van de Loosdrecht AA; Delwel R; Valk PJ; Sonneveld E; Kearns P; Creutzig U; Reinhardt D; de Bont ES; Coenen EA; van den Heuvel-Eibrink MM; Zwaan CM; Kaspers GJ; Cloos J; van den Berg TK
PLoS One; 2013; 8(1):e52143. PubMed ID: 23320069
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
[TBL] [Abstract][Full Text] [Related]
31. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.
Su R; Lin HS; Zhang XH; Yin XL; Ning HM; Liu B; Zhai PF; Gong JN; Shen C; Song L; Chen J; Wang F; Zhao HL; Ma YN; Yu J; Zhang JW
Oncogene; 2015 Jun; 34(25):3226-39. PubMed ID: 25174404
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia.
Fu Y; Xu M; Cui Z; Yang Z; Zhang Z; Yin X; Huang X; Zhou M; Wang X; Chen C
EBioMedicine; 2020 Feb; 52():102664. PubMed ID: 32062360
[TBL] [Abstract][Full Text] [Related]
33. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
34. HIV: CRISPR screen identifies novel therapeutic targets.
Crunkhorn S
Nat Rev Drug Discov; 2017 Feb; 16(2):88. PubMed ID: 28148946
[No Abstract] [Full Text] [Related]
35. Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia.
Yu Q; Xu Y; Zhuang H; Wu Z; Zhang L; Li J; Yang L; Wu B; Wang P; Zhang X; Gan X; Liang Y; Zheng S; Yu X; Gu Y; Xu R
Exp Cell Res; 2019 Nov; 384(2):111653. PubMed ID: 31574286
[TBL] [Abstract][Full Text] [Related]
36. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
37. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21).
Lu L; Wen Y; Yao Y; Chen F; Wang G; Wu F; Wu J; Narayanan P; Redell M; Mo Q; Song Y
Theranostics; 2018; 8(8):2189-2201. PubMed ID: 29721072
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial carrier homolog 2 is necessary for AML survival.
Khan DH; Mullokandov M; Wu Y; Voisin V; Gronda M; Hurren R; Wang X; MacLean N; Jeyaraju DV; Jitkova Y; Xu GW; Laister R; Seneviratne A; Blatman ZM; Ketela T; Bader GD; Marhon SA; De Carvalho DD; Minden MD; Gross A; Schimmer AD
Blood; 2020 Jul; 136(1):81-92. PubMed ID: 32299104
[TBL] [Abstract][Full Text] [Related]
39. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.
Wang T; Yu H; Hughes NW; Liu B; Kendirli A; Klein K; Chen WW; Lander ES; Sabatini DM
Cell; 2017 Feb; 168(5):890-903.e15. PubMed ID: 28162770
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
